Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study

References

• Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, et al.. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60:1644–9.
   PubMed Web of Science ®Google Scholar
• Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Fujii S, et al.. Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res. 2008;28:1309–15.
   PubMed Web of Science ®Google Scholar
• Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al.. Surgical outcomes in patients with T4 gastric carcinoma. J Am Coll Surg. 2006;202:223–30.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al.. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–57.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al.. ACTS-GC Group: adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–1820.
   PubMed Web of Science ®Google Scholar
• Giuliani F, Gebbia V, de Vita F, Maiello E, Di Bisceglie M, Catalano G, et al.. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res. 2003;23:4219–22.
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18:1673–9.
   PubMed Web of Science ®Google Scholar
• Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, et al.. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 2008;19:104–8.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al.. The V-325 Study Group: quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3210–6.
   PubMed Web of Science ®Google Scholar
• Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385–6.
   PubMed Web of Science ®Google Scholar
• Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, et al.. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 2011;117:2050–7.
   PubMed Web of Science ®Google Scholar
• Saitoh S, Sakata Y. Docetaxel and cisplatin in patients with advanced gastric cancer: results of Japanese phase I/II study. Gastr Cancer. 2002;5:23–6.
   PubMedGoogle Scholar
• Kunisaki C, Imada T, Yamada R, Hatori S, Ono H, Otsuka Y, et al.. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma. Anticancer Res. 2005;25:2973–7.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al.. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7.
   PubMed Web of Science ®Google Scholar
• Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–20.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191–7.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Yasui H, Goto A, Arai T, Ura T, Hamaguchi T, et al.. Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. Int J Clin Oncol. 2003;8:374–80.
   PubMedGoogle Scholar
• Kunisaki C, Takahashi M, Makino H, Oshima T, Fujii S, Takagawa R, et al.. Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol. 2011;67:1363–8.
   PubMed Web of Science ®Google Scholar
• Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al.. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.
   PubMed Web of Science ®Google Scholar
• Park KW, Ahn JS, Park YS, Lee J, Kang JH, Park JO, et al.. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Cancer Chemother Pharmacol. 2007;59:17–21.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer. 1996;32A:226–30.
   PubMed Web of Science ®Google Scholar
• Noguchi K, Iwahashi M, Tani M, Nakamura M, Nakamori M, Nakatani Y, et al.. Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay. Anticancer Res. 2005;25:931–7.
   PubMed Web of Science ®Google Scholar